Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

Denali Therapeutics Inc DNLI CEO Ryan Watts presented at the J.P. Morgan Healthcare Conference. The presentation primarily focused on the company’s blood-brain-barrier (BBB) crossing platform technology and the pipeline, including tividenofusp alfa (tivi, DNL310) in Hunter syndrome and DNL126 in Sanfilippo syndrome Type A, as well as ATV:Abeta approach in Alzheimer’s disease.Also Read: Denali Therapeutics’ Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was ExpectedJP Morgan notes th ...